ai3Bio launches with $48M for immune AI

ai3Bio launched with $48 million in Series A funding to develop AI-enabled treatments aimed at autoimmune disease. The company’s launch release says its discovery platform combines AI with immunology and remains preclinical, with IND-enabling safety studies underway before first-in-human trials; UPMC Enterprises’ account describes the same transition from research to company. Scientific-AI teams should file this as a capital-and-validation milestone, not a clinical result, alongside the archive’s drug-discovery financing analysis.